Beijing Sun-Novo Stock Hits Day High with Strong 5.04% Surge

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. has experienced a notable increase of 5.04% on March 16, 2026, reaching an intraday high of CNY 65.28. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 0.26% on the same day. Over the past week, Beijing Sun-Novo has shown a solid gain of 4.56%, while its one-year performance reflects a substantial increase of 47.61%, significantly outperforming the China Shanghai Composite, which rose by 19.45% during the same period. However, the stock's performance over the past month has been less favorable, with a decline of 2.73%. Despite the recent uptick, the company faces challenges in long-term growth, evidenced by a net sales decline of 24.97% in the most recent quarter. The company's return on equity stands at 14.05%, with a price-to-book ratio of 4.65, indicating a relatively high valuation. As a mid-cap player in the pharmaceuticals and biotechnology sector, Beijing Sun-Novo continues to navigate a complex market landscape.